Image
OXLUMO™ (lumasiran) Logo

OXLUMO™ is the first and only FDA-approved treatment for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels

OXLUMO has been shown to reduce urinary oxalate in infants, children, and adults with primary hyperoxaluria type 1 (PH1).1 By decreasing the production of oxalate in the liver, OXLUMO targets the underlying cause of the disease.1

Tell Me About OXLUMO Tell Me About PH1

Image
53%

Treatment with OXLUMO significantly reduced urinary oxalate (UOx) in patients with PH11

Treatment with OXLUMO resulted in a 53% reduction in 24-hour UOx excretion from baseline to month 6 for OXLUMO compared to placebo in a double-blind clinical trial of 39 patients aged >6 years with eGFR ≥30 mL/min/1.73 m2.*,1

Least squares mean reduction averaged over months 3 through 6, corrected for BSA (OXLUMO, 65%; placebo, 12%); 95% CI: 45%, 62%; P<0.0001 vs placebo.

Show Me the Data

The dosing regimen for OXLUMO led to a rapid reduction in 24-hr UOx within 2 weeks, which was sustained through 6 months1

After receiving 3 monthly starting doses, patients ≥10 kg received OXLUMO once per quarter.1

Show Me the Dosing Regimens

Image
'
Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist® Logo

Here for patients treated with OXLUMO

Alnylam Assist® can help your patients get access to OXLUMO and will provide support for patients throughout their treatment journey.

Let's Get Started

References: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc. 2. Milliner DS, Harris PC, Cogal AG, et al. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated November 30, 2017. Accessed November 16, 2020. 3. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271. 4. Hopp K, Cogal AG, Bergstralh EJ, et al; for Rare Kidney Stone Consortium. J Am Soc Nephrol. 2015;26(10):2559-2570. 5. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736.

Reference: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO™ (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.